Pregabalin has some beneficial effects in the management of neuropathic pain. However, there is an increased risk of adverse events and discontinuation because of adverse events. Igho Onakpoya In our recent systematic review [1], we searched for evidence from human trials that compared pregabalin with dummies in patients with neuropathic pain. We included studies of neuropathic […]
Category: Igho Onakpoya
Weight loss drugs effects on CVD remains unproven.
Approved weight-loss medications have only modest effects on cardiovascular risk. Igho Onakpoya One rationale for the development and marketing of weight loss drugs is that their use will improve cardiac risk factors. In a recent systematic review and network meta-analysis [1] of 28 randomised controlled trials (29,018 participants), the authors concluded that the effects […]
Seven ways to ensure faster removal of harmful medicines
Harmful medicines sometimes stay on the market for longer than they should. When that happens, people are unnecessarily exposed to medicines that may adversely affect their health. Igho Onakpoya The benefit-harm balance of new medicines is often not fully known at the time marketing licences are granted. More information about harms often becomes apparent […]
Rare adverse events in clinical trials: understanding the rule of three
Investigators should report rare and very rare adverse events in clinical trials: Igho Onakpoya reports why it is important that all events are reported irrespective of their frequency. Even though they may not give a signal in any single trial, a meta-analysis could reveal potentially important drug-adverse event associations that might require further […]